[go: up one dir, main page]

NO20050294L - New compounds useful in the treatment of obesity, type II diabetes and CNS disorders - Google Patents

New compounds useful in the treatment of obesity, type II diabetes and CNS disorders

Info

Publication number
NO20050294L
NO20050294L NO20050294A NO20050294A NO20050294L NO 20050294 L NO20050294 L NO 20050294L NO 20050294 A NO20050294 A NO 20050294A NO 20050294 A NO20050294 A NO 20050294A NO 20050294 L NO20050294 L NO 20050294L
Authority
NO
Norway
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
NO20050294A
Other languages
Norwegian (no)
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20050294L publication Critical patent/NO20050294L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår oppfinnelser med generell formel (1), hvori P er sulfon eller sulfonamid; og A, B, W, X, Y og R 3 er som definert i beskrivelsen; farmasøytiske sammensetninger innbefattende disse forbindelsene og anvendelsen av sammensetningene for profylakse og behandling av medisinske tilstander relatert til fedme, type II diabetes og/eller CNS-forstyrrelser, for å oppnå reduksjon av kroppsvekt og kroppsvektøkning.The present invention relates to inventions of general formula (1) wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R 3 are as defined in the specification; pharmaceutical compositions including these compounds and the use of the compositions for prophylaxis and treatment of medical conditions related to obesity, type II diabetes and / or CNS disorders, to achieve body weight reduction and body weight gain.

NO20050294A 2002-06-20 2005-01-19 New compounds useful in the treatment of obesity, type II diabetes and CNS disorders NO20050294L (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
NO20050294L true NO20050294L (en) 2005-02-04

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050294A NO20050294L (en) 2002-06-20 2005-01-19 New compounds useful in the treatment of obesity, type II diabetes and CNS disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA011581B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ552283A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315809C (en) 2002-03-27 2007-05-16 葛兰素集团有限公司 Quinoline derivatives and their use as 5-HT6 ligands
SE0301446D0 (en) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2005058858A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
CA2563895C (en) * 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
MX2008015510A (en) 2006-06-20 2008-12-18 Hoffmann La Roche Arylsulfonamidyl tetralin derivatives and uses thereof.
CA2654822A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
MX2008015843A (en) 2006-06-20 2009-01-09 Hoffmann La Roche Tetralin and indane derivatives and uses thereof.
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst Novel benzimidazole derivatives 290
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2617643C2 (en) * 2011-05-09 2017-04-25 ФОРМА ТиЭм, ЭлЭлСИ Novel compounds and compositions for inhibiting nampt
JP6454346B2 (en) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Aromatic heterocyclic compounds and their application in medicine
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
KR20180064373A (en) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 Diaryl and aryl heteroaryl urea derivatives as modulators of 5-HT2A serotonin receptors useful for the prevention and treatment of hallucinations associated with neurodegenerative diseases
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
DK0689536T3 (en) * 1993-03-16 2001-07-30 Pfizer naphtahlene
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
EP1278744A1 (en) * 2000-05-05 2003-01-29 Millenium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
JP2004503553A (en) * 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 6,5-fused bicyclic heterocycle
EP1326830A1 (en) * 2000-10-20 2003-07-16 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CA2443724C (en) * 2001-05-11 2009-11-03 Patrizia Caldirola Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
MXPA03011244A (en) * 2001-06-07 2004-02-27 Hoffmann La Roche New indole derivatives with 5-ht6 receptor affinity.
NZ529032A (en) * 2001-06-11 2007-04-27 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes

Also Published As

Publication number Publication date
RS111204A (en) 2006-12-15
EA008835B1 (en) 2007-08-31
SG156524A1 (en) 2009-11-26
MXPA04012914A (en) 2005-03-31
WO2004000828A1 (en) 2003-12-31
AU2003243091A1 (en) 2004-01-06
EA200500054A1 (en) 2005-06-30
CA2486989A1 (en) 2003-12-31
NZ536600A (en) 2007-08-31
EA200600975A1 (en) 2006-10-27
NZ552283A (en) 2008-07-31
CN1662521A (en) 2005-08-31
EP1513828A1 (en) 2005-03-16
IL165051A0 (en) 2005-12-18
EA011581B1 (en) 2009-04-28
NZ552282A (en) 2008-07-31
BR0311952A (en) 2005-04-19

Similar Documents

Publication Publication Date Title
NO20050294L (en) New compounds useful in the treatment of obesity, type II diabetes and CNS disorders
NO20075781L (en) Diarylsulfone sulfonamides and their use
SE0403006D0 (en) New compounds
NO20044763L (en) 1- (aminoalkyl) -3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
MXPA03011083A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes.
NO20050828L (en) indole-3-sulfur derivatives
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
NO20055649L (en) Substituted dihydroquinazoline with antivial properties
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
NO20062983L (en) Sulfonamide derivatives for the treatment of diseases
WO2003028641A3 (en) Mch receptor antagonists
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
NO20055680L (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
NO20063599L (en) Further heterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
NO20045042L (en) 7-aryl -3,9-diazabicyclo (3.1.1) non-6-ene derivatives and their use as renin. inhibitors in the treatment of hypertension, cardiovascular and kidney disease
NO20076515L (en) hydantoin
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20053792L (en) Heterocycly-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NO20071222L (en) Benzamide.
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
NO20060687L (en) New connections
NO20060718L (en) Substituted thiophones and their use
NO20080354L (en) Benzofuranyl derivatives as 5-HT6 receptor inhibitors
BRPI0508392A (en) Materials and Methods for Treating Coagulation Disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application